Published in Emerg Infect Dis on June 01, 2004
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev (2008) 3.52
Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2006) 1.81
Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol (2004) 1.66
Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol (2008) 1.36
Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients. J Clin Microbiol (2007) 1.32
A genome sequence survey shows that the pathogenic yeast Candida parapsilosis has a defective MTLa1 allele at its mating type locus. Eukaryot Cell (2005) 1.30
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital. PLoS One (2012) 1.27
Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J Clin Microbiol (2009) 1.27
Development of a gene knockout system in Candida parapsilosis reveals a conserved role for BCR1 in biofilm formation. Eukaryot Cell (2007) 1.14
Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. PLoS Pathog (2014) 1.13
Using RNA-seq to determine the transcriptional landscape and the hypoxic response of the pathogenic yeast Candida parapsilosis. BMC Genomics (2011) 1.10
Correlation between biofilm formation and the hypoxic response in Candida parapsilosis. Eukaryot Cell (2009) 1.06
Evolution of mating within the Candida parapsilosis species group. Eukaryot Cell (2011) 1.06
Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob Agents Chemother (2011) 1.06
Molecular genotyping of Candida parapsilosis group I clinical isolates by analysis of polymorphic microsatellite markers. J Clin Microbiol (2006) 1.04
New polymorphic microsatellite markers able to distinguish among Candida parapsilosis sensu stricto isolates. J Clin Microbiol (2010) 1.02
Fatty acid synthase impacts the pathobiology of Candida parapsilosis in vitro and during mammalian infection. PLoS One (2009) 0.99
Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children. Pediatr Infect Dis J (2012) 0.97
Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. J Antimicrob Chemother (2012) 0.96
Emergence of non-albicans Candida species in neonatal candidemia. N Am J Med Sci (2013) 0.93
Genotypic and phenotypic properties of Candida parapsilosis sensu strictu strains isolated from different geographic regions and body sites. BMC Microbiol (2010) 0.92
Unexpected genomic variability in clinical and environmental strains of the pathogenic yeast Candida parapsilosis. Genome Biol Evol (2013) 0.91
The role of Candida albicans AP-1 protein against host derived ROS in in vivo models of infection. Virulence (2013) 0.90
Biology and genetics of the pathogenic yeast Candida parapsilosis. Curr Genet (2009) 0.86
Isolates from hospital environments are the most virulent of the Candida parapsilosis complex. BMC Microbiol (2011) 0.83
Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother (2013) 0.82
Microsatellite genotyping clarified conspicuous accumulation of Candida parapsilosis at a cardiothoracic surgery intensive care unit. J Clin Microbiol (2012) 0.82
Candidemia distribution, associated risk factors, and attributed mortality at a university-based medical center. P R Health Sci J (2010) 0.80
Multiple Origins of the Pathogenic Yeast Candida orthopsilosis by Separate Hybridizations between Two Parental Species. PLoS Genet (2016) 0.79
A single-centre 10-year experience with Candida bloodstream infections. Can J Infect Dis Med Microbiol (2009) 0.79
Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-susceptible Candida parapsilosis isolates with different degrees of caspofungin susceptibility. Antimicrob Agents Chemother (2013) 0.79
Candidacidal activity of synthetic peptides based on the antimicrobial domain of the neutrophil-derived protein, CAP37. Med Mycol (2010) 0.79
Investigation of an unrecognized large-scale outbreak of Candida parapsilosis sensu stricto fungaemia in a tertiary-care hospital in China. Sci Rep (2016) 0.78
Candida parapsilosis corneal graft infection from a single eye center: Histopathologic report of 2 cases. Saudi J Ophthalmol (2015) 0.75
Antifungal Susceptibility Analysis of Clinical Isolates of Candida parapsilosis in Iran. Iran J Public Health (2016) 0.75
Regulation of ERG3, ERG6, and ERG11 Genes in Antifungal-Resistant isolates of Candida parapsilosis Iran Biomed J (2017) 0.75
Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol (1987) 13.21
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med (1991) 9.11
Computer-assisted methods for assessing strain relatedness in Candida albicans by fingerprinting with the moderately repetitive sequence Ca3. J Clin Microbiol (1990) 6.57
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis (1999) 3.92
Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis (1992) 3.68
Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res (2001) 3.57
Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis (1996) 3.50
Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J (2000) 3.13
Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev (2000) 3.05
The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev (2000) 2.95
Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun (2002) 2.94
Three distinct genotypes within Candida parapsilosis from clinical sources. J Clin Microbiol (1995) 2.13
Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis (1998) 2.12
Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med (1996) 2.09
Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol (1994) 1.91
Predictors of adverse outcome in cancer patients with candidemia. Am J Med (1998) 1.89
Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol (2002) 1.87
Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem (1998) 1.84
Ca3 fingerprinting of Candida albicans isolates from human immunodeficiency virus-positive and healthy individuals reveals a new clade in South Africa. J Clin Microbiol (2002) 1.81
Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B. Antimicrob Agents Chemother (1992) 1.67
Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol (1987) 1.58
Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis (1998) 1.57
Horizontal transmission of Candida parapsilosis candidemia in a neonatal intensive care unit. J Clin Microbiol (2002) 1.49
Biofilm formation by Candida dubliniensis. J Clin Microbiol (2001) 1.43
Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun (1995) 1.39
Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells. Infect Immun (1998) 1.31
Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun (1996) 1.29
Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis. J Clin Microbiol (2001) 1.27
An outbreak of Candida parapsilosis prosthetic valve endocarditis. Diagn Microbiol Infect Dis (1997) 1.26
Isolation, acid proteinase secretion, and experimental pathogenicity of Candida parapsilosis from outpatients with vaginitis. J Clin Microbiol (1989) 1.23
Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis (2002) 1.16
Individual acid aspartic proteinases (Saps) 1-6 of Candida albicans are not essential for invasion and colonization of the gastrointestinal tract in mice. Microb Pathog (2002) 1.15
Variations in DNA subtype, antifungal susceptibility, and slime production among clinical isolates of Candida parapsilosis. Diagn Microbiol Infect Dis (1995) 1.15
Electrophoretic karyotype analysis of sequential Candida parapsilosis isolates from patients with persistent or pecurrent fungemia. J Clin Microbiol (2001) 1.12
Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol (1999) 1.10
Evidence for differential expression of candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1-transgenic mice. J Infect Dis (2002) 1.07
Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of Candida albicans. Biochim Biophys Acta (1995) 1.04
Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains. Mycoses (2002) 1.01
Adhesion of Candida parapsilosis to epithelial and acrylic surfaces correlates with cell surface hydrophobicity. Mycoses (2001) 0.96
Molecular typing of Candida isolates from patients hospitalized in an intensive care unit. J Infect (2001) 0.94
Differential expression of Candida albicans phospholipase B (PLB1) under various environmental and physiological conditions. Microbiology (2003) 0.90
A retrospective study of seven cases of Candida parapsilosis peritonitis in CAPD patients: the therapeutic implications. Perit Dial Int (2000) 0.79
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol (2004) 4.51
Automatic electronic laboratory-based reporting of notifiable infectious diseases at a large health system. Emerg Infect Dis (2002) 3.88
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Antimicrobial-resistant nocardia isolates, United States, 1995-2004. Clin Infect Dis (2010) 3.15
The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis (2003) 3.04
In Candida albicans, white-opaque switchers are homozygous for mating type. Genetics (2002) 2.96
Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis (2012) 2.74
Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun (2003) 2.67
Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis--Ohio, 2010-2011. Clin Infect Dis (2012) 2.64
Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis (2012) 2.62
TOS9 regulates white-opaque switching in Candida albicans. Eukaryot Cell (2006) 2.42
Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA (2012) 2.36
Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother (2002) 2.26
Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2013) 2.20
Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother (2002) 2.20
Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. J Clin Microbiol (2003) 2.18
Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 2.03
Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol (2005) 2.00
Opaque cells signal white cells to form biofilms in Candida albicans. EMBO J (2006) 1.96
In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother (2004) 1.88
Assessment of ribosomal large-subunit D1-D2, internal transcribed spacer 1, and internal transcribed spacer 2 regions as targets for molecular identification of medically important Aspergillus species. J Clin Microbiol (2005) 1.86
Distinct roles for Dectin-1 and TLR4 in the pathogenesis of Aspergillus fumigatus keratitis. PLoS Pathog (2010) 1.84
Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine (2012) 1.81
Ca3 fingerprinting of Candida albicans isolates from human immunodeficiency virus-positive and healthy individuals reveals a new clade in South Africa. J Clin Microbiol (2002) 1.81
RT-PCR detection of Candida albicans ALS gene expression in the reconstituted human epithelium (RHE) model of oral candidiasis and in model biofilms. Microbiology (2004) 1.79
Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrob Agents Chemother (2004) 1.73
Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs (2004) 1.69
Early Impact of the US Tdap vaccination program on pertussis trends. Arch Pediatr Adolesc Med (2012) 1.69
In vitro growth and analysis of Candida biofilms. Nat Protoc (2008) 1.67
Functional specificity of Candida albicans Als3p proteins and clade specificity of ALS3 alleles discriminated by the number of copies of the tandem repeat sequence in the central domain. Microbiology (2005) 1.67
Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol (2004) 1.66
Candida biofilm resistance. Drug Resist Updat (2004) 1.65
Leptospirosis on Oahu: an outbreak associated with flooding of a university campus. Am J Trop Med Hyg (2007) 1.65
Pneumonia and septicemia caused by Burkholderia thailandensis in the United States. J Clin Microbiol (2006) 1.61
An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis (2005) 1.60
Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother (2003) 1.60
Combination treatment of invasive fungal infections. Clin Microbiol Rev (2005) 1.59
Waning immunity to pertussis following 5 doses of DTaP. Pediatrics (2013) 1.58
Population-based surveillance for cryptococcosis in an antiretroviral-naive South African province with a high HIV seroprevalence. AIDS (2006) 1.55
Candida albicans clades. FEMS Immunol Med Microbiol (2003) 1.55
Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg Infect Dis (2002) 1.53
Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother (2005) 1.52
Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother (2004) 1.49
Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med (2009) 1.48
Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. Clin Vaccine Immunol (2011) 1.47
Histoplasmosis associated with exploring a bat-inhabited cave in Costa Rica, 1998-1999. Am J Trop Med Hyg (2004) 1.47
Chromosome loss followed by duplication is the major mechanism of spontaneous mating-type locus homozygosis in Candida albicans. Genetics (2005) 1.44
Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis (2002) 1.43
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis (2011) 1.42
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) 1.40
Cutaneous infections dermatophytosis, onychomycosis, and tinea versicolor. Infect Dis Clin North Am (2003) 1.39
Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology (2007) 1.39
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol (2005) 1.37
Candida biofilm: a well-designed protected environment. Med Mycol (2005) 1.37
Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother (2006) 1.37
Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions. Antimicrob Agents Chemother (2007) 1.36
Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis (2006) 1.33
Alcohol dehydrogenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. Infect Immun (2006) 1.33
Heterozygosity of genes on the sex chromosome regulates Candida albicans virulence. Mol Microbiol (2007) 1.32
Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol (2004) 1.32
Allelic variation in the contiguous loci encoding Candida albicans ALS5, ALS1 and ALS9. Microbiology (2003) 1.31
Current epidemiology and trends in invasive Haemophilus influenzae disease--United States, 1989-2008. Clin Infect Dis (2011) 1.30
The same receptor, G protein, and mitogen-activated protein kinase pathway activate different downstream regulators in the alternative white and opaque pheromone responses of Candida albicans. Mol Biol Cell (2007) 1.27
Novel Brucella strain (BO1) associated with a prosthetic breast implant infection. J Clin Microbiol (2007) 1.27
Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics (2013) 1.25
Epidemiologic investigation and targeted vaccination initiative in response to an outbreak of meningococcal disease among illicit drug users in Brooklyn, New York. Clin Infect Dis (2009) 1.25
Outbreak of leptospirosis among Adventure Race participants in Florida, 2005. Clin Infect Dis (2010) 1.24
The yin and yang of paracetamol and paediatric immunisations. Lancet (2009) 1.22
Neisseria meningitidis serogroup W, Burkina Faso, 2012. Emerg Infect Dis (2014) 1.22
Resolution of discrepant results for Candida species identification by using DNA probes. J Clin Microbiol (2004) 1.21
Accuracy of real-time PCR, Gram stain and culture for Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae meningitis diagnosis. BMC Infect Dis (2013) 1.21
Brucellosis as a cause of acute febrile illness in Egypt. Trans R Soc Trop Med Hyg (2007) 1.20
Genes selectively up-regulated by pheromone in white cells are involved in biofilm formation in Candida albicans. PLoS Pathog (2009) 1.20
MyD88 regulation of Fusarium keratitis is dependent on TLR4 and IL-1R1 but not TLR2. J Immunol (2008) 1.19
Increased resistance of contact lens-related bacterial biofilms to antimicrobial activity of soft contact lens care solutions. Cornea (2009) 1.18
Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother (2011) 1.16
Analysis of ALS5 and ALS6 allelic variability in a geographically diverse collection of Candida albicans isolates. Fungal Genet Biol (2007) 1.16
Interaction of Candida albicans with adherent human peripheral blood mononuclear cells increases C. albicans biofilm formation and results in differential expression of pro- and anti-inflammatory cytokines. Infect Immun (2007) 1.16
In vitro activity of inexpensive topical alternatives against Candida spp. isolated from the oral cavity of HIV-infected patients. Int J Antimicrob Agents (2008) 1.16
Haemophilus haemolyticus isolates causing clinical disease. J Clin Microbiol (2012) 1.13
Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother (2008) 1.11
Drug resistance genes and trailing growth in Candida albicans isolates. J Antimicrob Chemother (2003) 1.10
Evidence for recombination in Candida glabrata. Fungal Genet Biol (2005) 1.10
Differentiation of tuberculous meningitis from acute bacterial meningitis using simple clinical and laboratory parameters. Diagn Microbiol Infect Dis (2006) 1.10
Phenotypic switching and mating type switching of Candida glabrata at sites of colonization. Infect Immun (2003) 1.09
Stability of allelic frequencies and distributions of Candida albicans microsatellite loci from U.S. population-based surveillance isolates. J Clin Microbiol (2003) 1.09